Search

Your search keyword '"Kournioti, Chryssanthi"' showing total 10 results
Start Over Author "Kournioti, Chryssanthi"
10 results on '"Kournioti, Chryssanthi"'

2. Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast).

Author

O'Donnell, Elizabeth, Shapiro, Yael, Comander, Amy, Isakoff, Steven, Moy, Beverly, Spring, Laura, Wander, Seth, Kuter, Irene, Shin, Jennifer, Specht, Michelle, Kournioti, Chryssanthi, Hu, Bonnie, Sullivan, Carol, Winters, Loren, Horick, Nora, and Peppercorn, Jeffrey

Abstract

Purpose: Retrospective analysis of nightly fasting among women with breast cancer suggests that fasting < 13 h may be associated with a higher risk of breast cancer recurrence. We sought to evaluate prolonged overnight fasting (POF), an accessible nonpharmacological intervention, in a prospective feasibility study. Methods: We designed a single-arm, pilot study to evaluate the feasibility of fasting for 13 h overnight for 12 weeks among women with a history of early-stage breast cancer survivors. Baseline and end of study assessments included measurements of body mass index (BMI), blood biomarkers, quality of life (QOL), mood, fatigue, and physical activity. Patient-reported outcome questionnaires were also administered at 6 weeks. Feasibility was defined as ≥ 60% of participants documenting fasting for 13 h on at least 70% of nights during the study period. Results: Forty women with a history of breast cancer were enrolled with a median age of 60 (range 35–76) and median time since diagnosis of 4.5 years (range 0.8–20.7). At baseline, BMI was ≥ 25 in 37.5%. Ninety-five percent of participants fasted ≥ 13 h for at least 70% of study days (95% CI 83–99%). There was a statistically significant improvement in anxiety (p = 0.0007) at 6 weeks and BMI (p = 0.0072), anxiety (p = 0.0141), depression (p = 0.0048), and fatigue (p = 0.0105) at 12 weeks. There was no significant change in overall QOL, physical activity levels, or blood biomarkers at 12 weeks. Conclusions: POF is feasible among patients with a history of breast cancer and may potentially improve BMI, mood, and fatigue without detrimental effects on overall QOL. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

3. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial

Author

Brown, Justin C., primary, Rosenthal, Michael H., additional, Ma, Chao, additional, Zhang, Sui, additional, Nimeiri, Halla S., additional, McCleary, Nadine J., additional, Abrams, Thomas A., additional, Yurgelun, Matthew B., additional, Cleary, James M., additional, Rubinson, Douglas A., additional, Schrag, Deborah, additional, Bullock, Andrea J., additional, Allen, Jill, additional, Zuckerman, Dan, additional, Chan, Emily, additional, Chan, Jennifer A., additional, Wolpin, Brian, additional, Constantine, Michael, additional, Weckstein, Douglas J., additional, Faggen, Meredith A., additional, Thomas, Christian A., additional, Kournioti, Chryssanthi, additional, Yuan, Chen, additional, Zheng, Hui, additional, Hollis, Bruce W., additional, Fuchs, Charles S., additional, Ng, Kimmie, additional, and Meyerhardt, Jeffrey A., additional

Published
2020
Full Text
View/download PDF

4. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer

Author

Ng, Kimmie, primary, Nimeiri, Halla S., additional, McCleary, Nadine J., additional, Abrams, Thomas A., additional, Yurgelun, Matthew B., additional, Cleary, James M., additional, Rubinson, Douglas A., additional, Schrag, Deborah, additional, Miksad, Rebecca, additional, Bullock, Andrea J., additional, Allen, Jill, additional, Zuckerman, Dan, additional, Chan, Emily, additional, Chan, Jennifer A., additional, Wolpin, Brian M., additional, Constantine, Michael, additional, Weckstein, Douglas J., additional, Faggen, Meredith A., additional, Thomas, Christian A., additional, Kournioti, Chryssanthi, additional, Yuan, Chen, additional, Ganser, Christine, additional, Wilkinson, Brittney, additional, Mackintosh, Christopher, additional, Zheng, Hui, additional, Hollis, Bruce W., additional, Meyerhardt, Jeffrey A., additional, and Fuchs, Charles S., additional

Published
2019
Full Text
View/download PDF

5. SUNSHINE: Randomized double-blind phase II trial of vitamin D supplementation in patients with previously untreated metastatic colorectal cancer.

Author

Ng, Kimmie, primary, Nimeiri, Halla Sayed, additional, McCleary, Nadine Jackson, additional, Abrams, Thomas Adam, additional, Yurgelun, Matthew B., additional, Cleary, James M., additional, Rubinson, Douglas Adam, additional, Schrag, Deborah, additional, Allen, Jill N., additional, Zuckerman, Dan Sayam, additional, Miksad, Rebecca A., additional, Chan, Emily, additional, Constantine, Michael, additional, Weckstein, Douglas, additional, Faggen, Meredith Gail, additional, Thomas, Christian A., additional, Kournioti, Chryssanthi S., additional, Mackintosh, Christopher, additional, Zheng, Hui, additional, and Fuchs, Charles S., additional

Published
2017
Full Text
View/download PDF

7. Rothman index as a predictor for type of discharge and readmission rates in a cancer hospital: The Yale experience.

Author

Morgensztern, Daniel, primary, Xia, Bing, additional, Kournioti, Chryssanthi S., additional, Hofstatter, Erin Wysong, additional, Raucci, Maureen, additional, Keyes, Ashley, additional, Morrione, Alienne, additional, Blasiak, Elizabeth, additional, Rosenberg, Elizabeth, additional, Rimar, Joan, additional, Rothman, Michael J, additional, and Lilenbaum, Rogerio, additional

Published
2013
Full Text
View/download PDF

10. Effect of High-Dose vs Standard-Dose Vitamin D 3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial.

Author

Brown JC, Rosenthal MH, Ma C, Zhang S, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin B, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Zheng H, Hollis BW, Fuchs CS, Ng K, and Meyerhardt JA

Abstract

Skeletal muscle and adipose tissue express the vitamin D receptor and may be a mechanism through which vitamin D supplementation slows cancer progression and reduces cancer death. In this exploratory analysis of a double-blind, multicenter, randomized phase II clinical trial, 105 patients with advanced or metastatic colorectal cancer who were receiving chemotherapy were randomized to either high-dose vitamin D 3 (4000 IU) or standard-dose (400 IU) vitamin D 3 . Body composition was measured with abdominal computed tomography at enrollment (baseline) and after cycle 8 of chemotherapy (16 weeks). As compared with standard-dose vitamin D 3 , high-dose vitamin D 3 did not significantly change body weight [-0.7 kg; (95% CI: -3.5, 2.0)], body mass index [-0.2 kg/m 2 ; (95% CI: -1.2, 0.7)], muscle area [-1.7 cm 2 ; (95% CI: -9.6, 6.3)], muscle attenuation [-0.4 HU; (95% CI: -4.2, 3.2)], visceral adipose tissue area [-7.5 cm 2 ; (95% CI: -24.5, 9.6)], or subcutaneous adipose tissue area [-8.3 cm 2 ; (95% CI: -35.5, 18.9)] over the first 8 cycles of chemotherapy. Among patients with advanced or metastatic colorectal cancer, the addition of high-dose vitamin D 3 , vs standard-dose vitamin D 3 , to standard chemotherapy did not result in any changes in body composition.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results